BIIB Biogen 2026 Outlook: Leqembi's Commercial Ramp and the Alzheimer's Market Reality Check
Biogen (BIIB) stock analysis for 2026. We evaluate Leqembi's actual prescription trajectory, the Spinraza revenue decline, Skyclarys rare disease growth, diranersen Phase 2 tau data, and whether the 55% bounce from $121 to $188 is justified.
BIIB Biogen Biotech